Rapastinel: Side Effects

Safety Overview#

Rapastinel demonstrated a favorable safety profile in clinical trials, particularly compared to ketamine. The absence of dissociative, psychotomimetic, and cognitive side effects was a key differentiator.

Adverse Events from Clinical Trials#

In the phase 2 trial, rapastinel at all tested doses was well tolerated. Reported adverse events were mild and included headache, nausea, and dizziness. The following ketamine-associated side effects were NOT observed:

• No psychotomimetic symptoms
• No dissociative symptoms
• No cognitive impairment
• No sedation
• No abuse potential signals

Safety Data Limitations#

The safety database is limited to approximately 430 subjects across 12 clinical trials with no long-term follow-up or post-marketing surveillance data.

Safety Profile Context#

Rapastinel belongs to the Neuropeptide category of research peptides. Understanding the side effect profile of Rapastinel is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.

Reported Side Effects#

The following side effects have been documented in clinical studies of Rapastinel. Side effect severity and frequency are based on available clinical data.

Headache#

Severity: mild | Frequency: common

Headache was among the most commonly reported adverse events in clinical trials, generally mild and self-limiting.

Nausea#

Severity: mild | Frequency: common

Mild nausea reported in some subjects following IV infusion.

Dizziness#

Severity: mild | Frequency: uncommon

Transient dizziness reported occasionally following IV administration.

Contraindications#

The following contraindications have been identified for Rapastinel based on available research and pharmacological considerations:

• Not approved for any therapeutic use (clinical development discontinued)
• Known hypersensitivity to rapastinel or any excipient

Individuals with any of these conditions should not use Rapastinel without consulting a qualified healthcare provider.

Drug Interactions#

The following potential drug interactions have been identified for Rapastinel:

• Concomitant antidepressants: Phase 3 trials evaluated rapastinel as adjunctive therapy; specific interaction data limited
• Other NMDA receptor modulators (ketamine, memantine): Theoretical pharmacodynamic interaction; concurrent use not studied

Drug interaction studies for Rapastinel remain limited. Researchers should exercise caution when combining Rapastinel with other compounds and consult relevant pharmacological references.

Related Reading#

• Rapastinel overview and research guide
• Rapastinel dosing protocols
• Rapastinel risks and legal status